GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Cash And Cash Equivalents

EV Biologics (EV Biologics) Cash And Cash Equivalents : $8.39 Mil (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Cash And Cash Equivalents?

EV Biologics's quarterly cash and cash equivalents declined from Dec. 2016 ($2.48 Mil) to Jun. 2017 ($1.81 Mil) but then increased from Jun. 2017 ($1.81 Mil) to Dec. 2017 ($8.39 Mil).

EV Biologics's annual cash and cash equivalents declined from Jun. 2015 ($16.47 Mil) to Jun. 2016 ($2.74 Mil) and declined from Jun. 2016 ($2.74 Mil) to Jun. 2017 ($1.81 Mil).


EV Biologics Cash And Cash Equivalents Historical Data

The historical data trend for EV Biologics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Cash And Cash Equivalents Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Cash And Cash Equivalents
5.79 19.73 16.47 2.74 1.81

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 2.66 2.48 1.81 8.39

EV Biologics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


EV Biologics  (OTCPK:YECO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


EV Biologics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of EV Biologics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Unveils NFT Dividend Warrant

By ACCESSWIRE ACCESSWIRE 07-26-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022